Orelabrutinib Not Yet Recruiting Phase 2 Trials for Bruton's Tyrosine Kinase / Immune Thrombocytopenia (ITP) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT05020288A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP